Dubuque Bank & Trust Co. Trims Stake in Merck & Co., Inc. (NYSE:MRK)

Dubuque Bank & Trust Co. reduced its position in Merck & Co., Inc. (NYSE:MRKGet Rating) by 1.2% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 10,246 shares of the company’s stock after selling 129 shares during the period. Dubuque Bank & Trust Co.’s holdings in Merck & Co., Inc. were worth $934,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Merck & Co., Inc. by 2.3% in the 1st quarter. Vanguard Group Inc. now owns 216,096,057 shares of the company’s stock valued at $17,730,682,000 after purchasing an additional 4,893,526 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Merck & Co., Inc. by 3.0% in the 1st quarter. BlackRock Inc. now owns 204,122,526 shares of the company’s stock valued at $16,748,252,000 after purchasing an additional 5,898,263 shares during the last quarter. State Street Corp lifted its holdings in shares of Merck & Co., Inc. by 2.7% in the 4th quarter. State Street Corp now owns 118,668,673 shares of the company’s stock valued at $9,174,491,000 after purchasing an additional 3,132,078 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Merck & Co., Inc. by 5.9% in the 1st quarter. Bank of New York Mellon Corp now owns 32,792,528 shares of the company’s stock valued at $2,690,627,000 after purchasing an additional 1,822,084 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Merck & Co., Inc. by 3.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 30,079,662 shares of the company’s stock valued at $2,468,037,000 after acquiring an additional 1,077,042 shares during the period. 73.33% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on MRK. Daiwa Capital Markets upgraded Merck & Co., Inc. from a “neutral” rating to a “buy” rating and boosted their price target for the company from $89.00 to $102.00 in a research report on Wednesday, July 6th. Cowen boosted their price target on Merck & Co., Inc. from $95.00 to $102.00 and gave the company a “market perform” rating in a research report on Monday, June 27th. Berenberg Bank upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and boosted their price target for the company from $95.00 to $100.00 in a research report on Wednesday, September 14th. Cowen boosted their price target on Merck & Co., Inc. from $95.00 to $102.00 and gave the company a “market perform” rating in a research report on Monday, June 27th. Finally, Morgan Stanley boosted their price target on Merck & Co., Inc. from $88.00 to $92.00 and gave the company an “equal weight” rating in a research report on Friday, July 29th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $98.28.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $87.51 on Friday. The business’s 50 day simple moving average is $88.83 and its 200-day simple moving average is $87.81. The firm has a market capitalization of $221.69 billion, a price-to-earnings ratio of 13.40, a price-to-earnings-growth ratio of 1.14 and a beta of 0.33. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.39 and a quick ratio of 1.15. Merck & Co., Inc. has a 12 month low of $71.50 and a 12 month high of $95.72.

Merck & Co., Inc. (NYSE:MRKGet Rating) last announced its quarterly earnings results on Thursday, July 28th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.67 by $0.20. The business had revenue of $14.59 billion for the quarter, compared to analyst estimates of $13.85 billion. Merck & Co., Inc. had a return on equity of 48.45% and a net margin of 29.00%. The company’s quarterly revenue was up 28.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.31 EPS. As a group, equities analysts forecast that Merck & Co., Inc. will post 7.33 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 15th will be paid a dividend of $0.69 per share. This represents a $2.76 annualized dividend and a dividend yield of 3.15%. The ex-dividend date is Wednesday, September 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 42.27%.

About Merck & Co., Inc.

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

See Also

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.